BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36055049)

  • 1. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
    Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
    ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
    Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
    Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
    Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
    Braczynski AK; Capper D; Jones DTW; Schittenhelm J; Stichel D; von Deimling A; Harter PN; Mittelbronn M
    Pathol Res Pract; 2020 Jan; 216(1):152728. PubMed ID: 31784096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
    Bady P; Delorenzi M; Hegi ME
    J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.
    Hamilton MG; Roldán G; Magliocco A; McIntyre JB; Parney I; Easaw JC
    J Neurooncol; 2011 Apr; 102(2):255-60. PubMed ID: 20652362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
    Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
    Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W
    Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
    Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
    Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
    Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.